Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the ...

Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on chromosomal instability, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase ...

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, ...

Repeated positive recommendation from Data Safety Monitoring Board ("DSMB") of pivotal Phase 3 study for lead clinical ...

Welcome to The Pharma Letter ’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for ...

Recludix Pharma, a leader in the discovery of inhibitors for challenging targets in inflammatory disease, today announced a ...

Kura Oncology, Inc. (Nasdaq: KURA, "Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin”) today announced that an a ...

Zai Lab Limited gains momentum with FDA Fast Track nod and solid earnings, signaling growth potential. Click here to find out ...